Due to extremely high demand, we created a second webinar on regulatory compliance. So, if you have not registered for our November 24th, 2020 webinar, we encourage you to register for this one, which will take place on December 2, 2020 at 6:30 pm PST. Both seminars have the same agenda. But we want to
RxPolicy – a compliance platform
We are very excited to announce a launching of a website for pharmacy compliance: RxPolicy. It assists pharmacies with ever-growing compliance requirements. Pharmacies can download the pharmacy operational manual in full with automatic yearly updates or can just pick one policy. Policies will be updated on a yearly basis and new policies and documents to
Highlights of the 2019 American Society for Pharmacy Law Conference
As always, the American Society for Pharmacy Law (“ASPL”) gathered pharmacy attorneys and pharmacists for an excellent three-day conference focusing on pharmacy legal issues. Some of the highlights of the conference:
Regulatory updates: Despite various state and federal attempts to lower drug prices, they continue to grow mostly due to high deductible plans, cost-sharing, increased
Complimentary legal services to pharmacies affected by California Fires and pharmacists working with evacuees.
Our hearts go to all affected by wildfires raging through California. Thousands are evacuated and in need of medical care and access to medications. While we acknowledge our first responders, we must also show appreciation to our pharmacists responding to the disaster. They are working tirelessly at the front lines helping vulnerable patients, providing medications,
Your pharmacy’s chance to stop below-cost and unfair reimbursements
A survey conducted by the National Community Pharmacists Association (NCPA) revealed that almost all independent pharmacies experience significant increase in drug acquisition cost while reimbursements are not simultaneously adjusted to reflect the increase. Often, reimbursements are adjusted but with remarkable delays. When pharmacies appeal these MAC reimbursements and delays in adjusting generic pricing, the appeals
Avoiding iabilities when measuring blood-glucose
This month, I will be presenting a series of webinars organized by Nova Biomedical aimed to educate healthcare practitioners on what constitutes off-label use of blood-glucose meters (BGM). My part of the presentation will focus on the risks associated with the off-label use of BMGs and the ways to avoid potential liabilities.
Why did
10 Complimentary Passes to a Webinar on Controlled Substances
Please join me for a live webinar, “Opioids and Other Controlled Substances: Minimizing the Risks in Prescribing, Dispensing and Administering” scheduled for Wednesday, April 17, 1:00pm-2:30pm EDT.
I will be speaking on new regulations and practices pertaining to TeleHealth and e-prescribing. My co-speakers include: Kerry B. Harvey, Member at Dickinson Wright; Lindsay P. Holmes
You are invited! A webinar on prescribing, dispensing and administering controlled substances
I am pleased to announce that I will be speaking in an upcoming Strafford live webinar, “Opioids and Other Controlled Substances: Minimizing the Risks in Prescribing, Dispensing and Administering” scheduled for Wednesday, April 17, 1:00pm-2:30pm EDT.
Because of your affiliation with my firm, you are eligible to attend this program at half off. As
You are Invited: Pharmacy Law Conference
Natalia will be speaking at the largest pharmacy law conference organized by the American Society for Pharmacy Law. The subject of her talk is “Your Pharmacy is Being Audited by DEA – Complying, Defending, and Prevailing!” Natalia will focus on:
– differences between DEA’s administrative actions and criminal prosecution;
– how to avoid the case
You are invited to a webinar: “Prescription Audits: When the DEA or AG Come Knocking”
I am pleased to announce that I will be speaking in an upcoming Strafford live webinar, “Prescription Audits: When the DEA or AG Come Knocking” scheduled for Wednesday, August 22, 1:00pm-2:30pm EDT.
The Drug Enforcement Administration (DEA) and state attorneys general (AGs) are increasing scrutiny on medical providers at all levels who are involved in